Should atezolizumab and nab-paclitaxel now be used in first line therapy for metastatic, triple negative breast cancer?  

There's a great discussion (and criticism) of this study in a new podcast "Plenary Session". I would highly recommend listening to the first half of the episode from 10/23/18.

The study clearly shows the benefit of adding the atezolizumab to chemotherapy in first line TNBC. However, how much can you generalize the study results remain to be unknown. There are five other randomized clinical trials with a checkpoint inhibitor combined with chemotherapy. These studies will h...